



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



CD55 (h): 293T Lysate: sc-175132

BACKGROUND

CD55, also called decay accelerating factor (DAF), is a GPI-anchored single chain glycoprotein. CD55 may play a role in protecting cells from complement-mediated lysis by preventing the amplification steps of the complement cascade. CD55 functions to prevent the assembly of C3 convertase or to accelerate the disassembly of preformed convertase, which blocks formation of the membrane attack complex. CD55 is expressed on cells in contact with serum, including hematopoietic and many non-hematopoietic cells.

REFERENCES

1. Seya, T., Matsumoto, M., Hara, T., Hatanaka, M., Masoaka, T. and Akedo, H. 1994. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF) in hematological malignancies. *Leuk. Lymphoma* 12: 395-400.
2. Nicholson-Weller, A. and Wang, C.E. 1994. Structure and function of decay accelerating factor CD55. *J. Lab. Clin. Med.* 123: 485-491.
3. Bjorge, L., Jensen, T.S. and Matre, R. 1996. Characterization of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. *Cancer Immunol. Immunother.* 42: 185-192.
4. Spiller, O.B., Moretto, G., Kim, S.U., Morgan, B.P. and Devine, D.V. 1996. Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. *J. Neuroimmunol.* 71: 97-106.
5. van Denderen, B.J., Pearse, M.J., Katerelos, M., Nottle, M.B., Du, Z.T., Aminian, A., Adam, W.R., Shenoy-Scaria, A., Lublin, D.M., Shinkel, T.A. and d'Apice, A.J. 1996. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. *Transplantation* 61: 582-588.
6. Kuttner-Kondo, L., Medof, M.E., Brodbeck, W. and Shoham, M. 1996. Molecular modeling and mechanism of action of human decay-accelerating factor. *Protein Eng.* 9: 1143-1149.
7. Liszewski, M.K., Farries, T.C., Lublin, D.M., Rooney, I.A. and Atkinson, J.P. 1996. Control of the complement system. *Adv. Immunol.* 61: 201-283.

CHROMOSOMAL LOCATION

Genetic locus: CD55 (human) mapping to 1q32.2.

PRODUCT

CD55 (h): 293T Lysate represents a lysate of human CD55 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

CD55 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive CD55 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.